Clinical Value Of Joint Detection Of Serum CA19-9、CEACAM1、 REG4in Diagnosis Of Pancreatic Cancer

Background: Early diagnosis of pancreatic cancer is very difficult.When the examinations such as computed tomography (CT) and othermedical imaging methods have not yet been checked out positive results,tumor markers in the blood may already have different degrees ofincrease. But there is no one kind of tumor makers that showed acompletely specific for certain tumors, so early diagnosis of pancreaticcancer is extremely important. For a long time, people have always beenlooking for a way to early diagnosis of malignant tumor, in which thedetection of serum tumor markers is of great value. Thus the clinicurgently needs effective joint detection in order to improve the rate ofearly diagnosis and overall treatment effect.Objective: Explore the clinical value of joint detection of serumCA19-9, CEACAM1, REG4in diagnosis of pancreatic cancer.Methods: Respectively using chemiluminescence immunoassay andenzyme-linked immunoassay (ELISA) to detect serum levels of CA19-9,CEACAM1and REG4among34cases of pancreatic cancer,26cases ofchronic pancreatitis and20healthy individuals, and then doing thestatistical analysis of test results. Results:1. The serum levels of CA19-9, CEACAM1and REG4in pancreaticcancer group are obviously higher than that in chronic pancreatitisand healthy individuals groups. As for single detection indicator,the sensitivity and specificity of CA19-9are respectively85.3%and77.0%; CEACAM respectively for82.4%and69.2%; REG4respectively for79.4%and84.6%. The sensitivity of CA19-9(85.3%) and the specificity of REG4(84.6%) are the highestrespectively. Doing parallel tests in the joint detection of thesethree tumor markers (TMs) can improve the sensitivity andnegative predictive value, while series tests in the joint detectioncan improve the specificity and positive predictive value.2. The differences among the levels of three type of tumor markersin different clinical stages of pancreatic cancer patients arestatistically significant (P<0.01), and the levels of three type oftumor markers in different stages from low to high: I stage <IIstage <III stage<IV stage.3. The serum levels of CA19-9, CEACAM1and REG4are notaffected by tumor size, the differences of which are notstatistically significant (P>0.05). The serum levels of CA19-9inpancreatic tail cancer patients are obviously higher than that inpancreatic head cancer and whole pancreatic cancer patients, which is statistically significant (P<0.05), while the serum levelsof CEACAM1and REG4in different position of pancreaticcancer have no significant difference (P<0.01).4. Using ROC curve method to process the detection results of threetypes of tumor markers. The AUC of CA19-9, CEACAM1, REG4are respectively0.931,0.901and0.942.Conclusion: Joint detection of CA19-9, CEACAM1, and REG canimprove the sensitivity and specificity of diagnosis of pancreatic cancer,and also the clinical value. It is a good indicator in the early clinicaldiagnosis of pancreatic cancer.